Table 6.

The Cox regression analysis to identify the predictors of mortality in the patients with cancer therapy-related cardiomyopathy.

Predictors of mortality
	Univariate			Multivariate
	HR	CI 95%	p -value	HR	CI 95%	p -value
Age (1 year)	1.01	0.98–1.03	0.69	1.01	0.98–1.05	0.482
Female sex	1.24	0.54–2.84	0.62
No smoking history	1.03	0.42–0.25	0.96
Arterial hypertension	1.00	0.35–2.88	0.99
Dyslipidemia	5.58	0.76–40.78	0.09	5.73	0.78–42.0	0.09
Diabetes	1.12	0.15–8.32	0.92
BMI (1 kg/m2)	0.88	0.63–1.22	0.44
Baseline LVEF (1%)	0.97	0.90–1.03	0.31
LVEF at the time of diagnosis of CTRCD (1%)	0.94	0.91–0.97	0.001	0.94	0.91–0.97	0.0001
Trastuzumab treatment	1.83	0.84–3.98	0.14	2.25	1.02–4.96	0.045
Anthracyclines treatment	1.88	0.95–3.70	0.07	1.56	0.78–3.12	0.212
Thoracic radiotherapy	1.37	0.70–2.67	0.35
HF admission at diagnosis	1.64	0.77–3.51	0.20
Cardiac specific treatment	0.75	0.29–1.99	0.56
Beta-blocker treatment	0.79	0.38–1.63	0.52
Carvedilol treatment	0.43	0.05–3.49	0.43
ACE-I treatment	1.58	0.70–3.60	0.27
ARB treatment	0.21	0.03–1.55	0.13
MRA treatment	1.95	0.83–4.59	0.13
Time from starting chemotherapy to dysfunction (1 month)	1.00	0.99–1.01	0.72
LVEF recovery during follow-up	1.33	0.54–1.33	0.53
HF admission during follow-up	1.09	0.32–3.73	0.89

ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; CI, confidence interval; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.

Cardiac-specific treatment meant to receive at least ACE-I/ARB after CTRCD diagnosis. Bold means statistically significant (p <0.05).